MSOS: Pause On Cannabis Rescheduling - And Why Trulieve Is A Sneaky Pick

The analyst reiterated a Buy rating on AdvisorShares Pure US Cannabis ETF (MSOS) despite the DEA pausing cannabis-rescheduling hearings. The delay is characterized as postponement rather than cancellation, while MSOS holdings are viewed as reasonably valued. Largest holding Trulieve Cannabis is highlighted for its Florida medical-sales exposure and normalized tax rates.

Analysis

The key valuation error in U.S. cannabis remains treating a procedural rescheduling path as equivalent to near-term cash-tax relief. Until a final rule is effective, 280E continues to absorb operating cash flow; even then, state-law illegality, banking constraints, and exchange-listing limitations may persist. MSOS therefore retains asymmetric upside to a definitive regulatory action, but its NAV will remain unusually sensitive to headline-driven probability changes rather than underlying earnings over the next 1-3 months.

TCNNF has the cleanest near-term idiosyncratic setup because Florida remains its largest earnings engine and its medical-heavy mix can support superior local density economics. The second-order issue is that Florida optionality is not free: a renewed adult-use ballot campaign could raise marketing spend and invite competitive capacity investment before any revenue benefit arrives. GTBIF is the more defensive alternative within the group, with broader state diversification and less dependence on a single binary state catalyst; CURLF and VRNOF offer higher operating leverage if federal reform improves tax economics, but carry greater execution and balance-sheet sensitivity.

Contrary to the bullish framing, rescheduling alone should not justify a broad multiple re-rating comparable to a full legalization event. The market is likely underestimating the time between administrative progress and actual cash-tax changes, while also overestimating the probability that institutional capital can immediately enter the sector. The more durable 6-18 month upside requires evidence of post-280E free-cash-flow conversion, debt refinancing at materially lower rates, and state-level demand growth—not simply a favorable DEA headline.

Key Decisions for Investors

• Do not chase MSOS on procedural headlines; build only on weakness after confirming the next formal DEA docket date and legal timeline. Size as a 6-12 month catalyst position, with a 50-100% upside case on effective tax reform but substantial drawdown risk if the process moves into litigation or the 2026 political calendar.
• Prefer a relative-value basket long GTBIF and TCNNF versus MSOS for investors seeking cannabis exposure over the next 3-6 months. This reduces ETF-level swap/liquidity and weaker-operator exposure while retaining regulatory upside; reassess if Florida medical trends weaken or either company guides to deteriorating adjusted EBITDA.
• For higher-beta exposure, use a small long TCNNF position only if Florida same-store sales and gross-margin trends stabilize; the thesis is falsified by sustained share loss, renewed cash-tax pressure, or ballot-related spending that materially reduces free cash flow.
• Treat any final effective rescheduling rule—not an announcement, hearing, or recommendation—as the trigger to add sector exposure. At that point, prioritize operators with net debt refinancing needs and meaningful 280E burdens, where lower cash taxes can most quickly improve leverage metrics and equity multiples.